Stock Rating Downgrade
Reflecting eroding fundamentals and low Appreciation Potential, the Value Trend Rating for Jazz Pharmaceuticals plc (NASDAQ: JAZZ) weakened in the last week. JAZZ’s current Value Trend Rating is C and the prior Rating was B. Details supporting this lower rating are included in our next report.
Recent Price Action
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) stock closed at $115.09 on 4/8/24 after a modest decline of -1.1%. However, this decline was accompanied by below average trading volume at 72% of normal. The stock has been weak relative to the market over the last nine months and has declined -4.4% during the last week.
Current PriceTarget Research Rating
JAZZ is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Jazz Pharmaceuticals plc has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Jazz Pharmaceuticals plc has a good Appreciation Score of 84 but a poor Power Rating of 30, resulting in the Neutral Value Trend Rating.
Be the first to comment